What Happens at a Breast Augmentation Consultation - and Why the Call Before It Decides Whether She Books

The consultation is not where a breast augmentation decision begins. It is somewhere in the middle of one.

Before she books, a prospective patient has usually read the American Society of Plastic Surgeons list of eighteen questions she is told to ask her surgeon. She may know that the U.S. Food and Drug Administration requires a boxed warning on every breast implant sold in this country, and that she will be asked to initial and sign a Patient Decision Checklist before surgery. She has seen the words BIA-ALCL. She has encountered the phrase "breast implants are not lifetime devices," because the FDA put it there.

Then she picks up the phone, asks a question, and finds out whether the practice is equal to the decision she is carrying.

That call is the product. Everything downstream of it is fulfillment.

A breast augmentation consultation is a structured medical evaluation, not a sales appointment

The visit itself is fairly consistent across accredited practices. The surgeon takes a medical history, examines and measures the chest wall and breast tissue, and discusses implant type, size, profile, surface texture, incision site and placement relative to the pectoralis muscle. The American Society of Plastic Surgeons frames these as the specific decisions to settle with the surgeon: "What shape, size, surface texturing, incision site and placement site are recommended for me?"

Two things happen that most prospective patients do not anticipate.

The first is sizing. Practices using the MENTOR Volume Sizing System work from eighteen reusable sizing devices, nine per breast, tried on in the office. Allergan's Natrelle sizers are re-sterilizable and approved for temporary use only. This is a physical, iterative process, and it is the reason the consultation cannot be replaced by a phone call or a photograph.

The second is the regulatory paperwork. Since the FDA's October 2021 orders restricting the sale and distribution of breast implants, every patient must be walked through a Patient Decision Checklist by the provider, initialling each section and signing it. The checklist is not a formality. It states plainly that "as many as 20 percent of women who receive breast implants for augmentation have to have their implants removed within 8 to 10 years, but my implants may last for a shorter or longer time."

The FDA-mandated disclosures are heavier than most practices assume, and they shape the call

The boxed warning the FDA approved in 2021 tells the patient three things: that breast implants are not considered lifetime devices; that they have been associated with breast implant-associated anaplastic large cell lymphoma, a cancer of the immune system, more commonly with textured than smooth implants, and that some patients have died from it; and that patients have reported systemic symptoms including joint pain, fatigue and cognitive difficulty, for which individual risk has not been well established.

The long-term device data is consistent with that framing. In the Mentor MemoryGel Core Study, published in Plastic and Reconstructive Surgery in 2021, the primary augmentation cohort of 552 patients showed a ten-year cumulative reoperation rate of 25.5 percent and a rupture rate of 24.2 percent. The Natrelle 410 Core Study, published in Aesthetic Surgery Journal in 2015 with 492 primary augmentation subjects, found a ten-year reoperation rate of 29.7 percent. Both are manufacturer-sponsored core studies and both are peer-reviewed. The Natrelle 410 cohort retained only 65.8 percent of subjects at ten years, which is a real limitation worth stating.

A woman who has read any of this is not making a casual booking call. She is making a call about a decision with a documented reoperation curve attached to it. A practice that answers on the fourth ring with someone who cannot tell her whether the consultation fee is credited toward surgery has misjudged the moment.

Cosmetic consultations converted worst of the five categories measured in the largest published dataset, which is why the call matters more here

There is one large peer-reviewed dataset on this. A 2014 analysis in Plastic and Reconstructive Surgery examined 12,020 new-patient consultations and 5,741 surgical cases at a single academic centre over eight years. Aesthetic consultations converted to surgery at 37.0 percent, plus or minus 4.8. Breast reconstruction converted at 57.0 percent, oncologic cases at 56.9 percent, burn and trauma at 47.0 percent, and general cases at 46.1 percent. Aesthetic was the lowest of the five.

This is a single-centre academic figure, not a national benchmark, and it should not be presented as one. But the direction is not in dispute and the reason is not mysterious. Reconstruction patients have a diagnosis. Cosmetic patients have an option, and an option can be deferred indefinitely.

Run the arithmetic on what that means for a booked consultation. The ASPS 2024 Plastic Surgery Statistics Report puts the average surgeon fee for breast augmentation with implants between $4,575 and $8,000, and that is the surgeon's fee alone, before facility and anaesthesia. At a 37 percent conversion rate, every consultation that never gets booked is worth roughly $1,700 to $3,000 in expected surgeon fee. Illustrative model, using published ASPS fee data and a single-centre conversion rate. Not a client result or a guarantee.

A practice fielding thirty augmentation inquiries a month that loses four of them to an unanswered phone is not losing four phone calls. On that model it is forgoing somewhere near $7,000 to $12,000 in expected surgeon fee, every month, from calls that already happened.

Patients self-select into practices that make the pre-consultation experience feel considered

The clearest evidence for this comes from an unexpected place. A prospective study published in Plastic and Reconstructive Surgery in 2018 set out to test whether three-dimensional imaging simulation improved outcomes in primary breast augmentation. It enrolled 100 women over three years, but only 23 accepted randomisation, because once patients learned 3D simulation existed, most refused to be assigned away from it.

The finding was that 3D simulation, using systems such as the VECTRA XT from Canfield Scientific, did not meaningfully improve BREAST-Q satisfaction scores compared with conventional planning. Both groups rose from roughly 20 to roughly 85 on a 100-point scale.

Read that carefully, because it is the whole argument. The technology did not change the outcome. It changed who was willing to proceed. Patients demanded it before they would commit. In this category, the pre-consultation experience is not a preamble to the product. For the purposes of getting booked, it is the product.

Which raises the obvious question about the part of the pre-consultation experience that happens before any imaging system is switched on: the phone.

Nobody has actually measured phone handling in aesthetic surgery, and the number the industry quotes is not a study

Here is something worth saying out loud, because the alternative is repeating a figure that will not survive scrutiny.

A search of Aesthetic Surgery Journal and Plastic and Reconstructive Surgery returns no study on missed-call rates, call answer speed, or after-hours call volume in plastic surgery practices. As far as we can establish, the question has never been measured in the peer-reviewed literature. The statistic circulating throughout aesthetic marketing, that medical practices miss 42 percent of incoming calls during business hours, is attributed to Physician Growth Accelerator, a practice-marketing consultancy and podcast rather than a research organisation. We have been unable to locate any published dataset, methodology or sample description behind it, and we would revise this the day one is produced. The same is true of most of the adjacent numbers: the share of calls arriving after hours, the share of callers who hang up rather than leave voicemail, the share who dial a competitor next.

The nearest defensible evidence is not from healthcare at all. In a Harvard Business Review study published in 2011, researchers audited 2,241 U.S. companies by submitting a test web enquiry. Twenty-three percent never responded at all. Among those that did respond within thirty days, the average response time was 42 hours. A separate dataset of 1.25 million sales leads across 42 companies found that contacting a lead within an hour made a firm roughly seven times more likely to qualify it than waiting one additional hour.

That is not a plastic surgery study and should never be presented as one. What it establishes is narrower and still useful: across thousands of businesses that believed they were responsive, a quarter simply never answered, and the ones that did took the better part of two days.

The honest position is that the leak in aesthetic intake is unmeasured, not that it is 42 percent. Which is precisely why a practice should measure its own rather than inherit someone else's number. That is the entire premise of an Intake Leak Audit: we call your main line after hours and document what actually happens.

This frees your patient coordinator, it does not replace her

A patient coordinator who is good at breast augmentation consultations is one of the most valuable people in a plastic surgery practice. She reads hesitation, handles the partner in the room, senses when a size request is a body-image conversation rather than a volume conversation, and knows when to slow a patient down. None of that is automatable, and nothing here proposes automating it.

The argument is the opposite one. That person should not be the reason a Tuesday evening caller reaches voicemail while the coordinator is in an operating suite or mid-consultation with someone else. A structured intake layer answers the call that would otherwise go unanswered, captures the clinical and logistical basics, confirms whether the caller is asking about a primary augmentation or a revision, books against real availability, and hands a prepared patient to a human being who now has context instead of a callback list.

That is the Zero-Miss Intake Protocol applied to a surgical vertical where a single captured consultation carries four figures of expected surgeon fee. The same structure that governs a lip filler consultation call has to be tuned differently here, because the decision timeline is months rather than days, and the questions are heavier.

The related failure modes are worth reading alongside this: how practices lose consults specifically at the consultation booking step, what happens when the caller opens with the cost question, how virtual consultation requests get routed, and what a caller is really testing when she asks how to choose a plastic surgeon.

Frequently asked questions

What happens at a breast augmentation consultation? The surgeon takes a medical history, examines and measures the breast and chest wall, and works through implant type, size, profile, surface texture, incision site and placement. Most practices include in-office sizing with reusable sizing devices, and many offer 3D imaging simulation. The FDA-required Patient Decision Checklist is reviewed, initialled and signed with the provider before surgery.

How long does a breast augmentation consultation take? Practices vary. The elements that consume the time are the physical examination, the sizing session and the FDA-required checklist review, which is why practices that schedule it like a fifteen-minute intake appointment tend to run over.

Is a breast augmentation consultation free? It depends on the practice. The Aesthetic Society's patient guidance states that there will most likely be a fee, and that the surgeon's office will often deduct it from the cost of the procedure. No published survey quantifies how many practices credit the fee or what the typical fee is, so the only reliable way to find out is to ask the practice directly. That it is one of the most common first questions on the phone is itself worth noting.

What should I ask at a breast augmentation consultation? The American Society of Plastic Surgeons publishes eighteen questions, including whether the surgeon is certified by the American Board of Plastic Surgery, whether the surgical facility is accredited, what shape, size, texturing, incision and placement are recommended, how long recovery takes and what help will be needed, and how many additional implant-related operations can be expected over a lifetime.

How long do breast implants last? The FDA states that breast implants are not lifetime devices. Its Patient Decision Checklist notes that as many as 20 percent of augmentation patients have implants removed within eight to ten years, while adding that an individual's implants may last a shorter or longer time. Ten-year core study data reported reoperation rates of 25.5 percent for Mentor MemoryGel and 29.7 percent for Natrelle 410 in their primary augmentation cohorts.

What are gummy bear implants? "Gummy bear" is a patient-facing nickname, not an FDA term. The FDA-approved designation for the device usually meant is the Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implant. The FDA notes only that silicone gel viscosity differs among implants and manufacturers.

References

• American Society of Plastic Surgeons, 2024 Plastic Surgery Statistics Report. Breast augmentation 306,196 procedures; average surgeon fee $4,575 to $8,000. Survey of ASPS member surgeons, approximately 1,000 responses, margin of error plus or minus 4.62 percent.

• American Society of Plastic Surgeons, "Questions to ask your plastic surgeon about breast augmentation."

• U.S. Food and Drug Administration, "FDA Strengthens Safety Requirements and Updates Study Results for Breast Implants," 27 October 2021; and "Breast Implants - Certain Labeling Recommendations to Improve Patient Communication," guidance issued 29 September 2020, Appendices A and B.

• Caplin DA, Calobrace MB, Wixtrom RN, Estes MM, Canady JW. "MemoryGel Breast Implants: Final Safety and Efficacy Results after 10 Years of Follow-Up." Plastic and Reconstructive Surgery, March 2021;147(3):556-566. Primary augmentation cohort n=552.

• Maxwell GP, Van Natta BW, Bengtson BP, Murphy DK. "Ten-Year Results from the Natrelle 410 Anatomical Form-Stable Silicone Breast Implant Core Study." Aesthetic Surgery Journal, 2015;35(2):145-155. Primary augmentation cohort n=492; 10-year follow-up 65.8 percent.

• "The Differential Impact of Plastic Surgery Subspecialties on the Financial Performance of an Academic Clinical Practice." Plastic and Reconstructive Surgery, June 2014. 12,020 consultations, 5,741 surgical cases, single academic centre, 2004-2012.

• Overschmidt B, Qureshi AA, Parikh RP, Yan Y, Tenenbaum MM, Myckatyn TM. "A Prospective Evaluation of Three-Dimensional Image Simulation: Patient-Reported Outcomes and Mammometrics in Primary Breast Augmentation." Plastic and Reconstructive Surgery, August 2018.

• Oldroyd JB, McElheran K, Elkington D. "The Short Life of Online Sales Leads." Harvard Business Review, March 2011. Audit of 2,241 U.S. companies; separate dataset of 1.25 million leads across 42 companies. Not a healthcare study.

• The Aesthetic Society, patient resources, plastic surgery costs guidance.

• Mentor Worldwide / Johnson & Johnson MedTech, MENTOR Volume Sizing System product information; Allergan / AbbVie, NATRELLE Re-Sterilizable Breast Implant Sizers Directions for Use.

Next Step

If your premium practice runs more than 100 inbound consult inquiries a month and has no structured measurement of how many never reach a scheduled consultation, your pipeline is leaking revenue. We quantify this for your practice in a 30-minute Intake Leak Audit.

• Request an Intake Leak Audit: expand@thethinkingrobot.com

• Audit Real-Time Conversational Velocity: Talk to Rosey, our AI receptionist, at +1 (720) 776-1664.